Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Liabilities and Shareholders Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $244.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 37.03% to $244.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 billion, a 20.87% decrease, with the full-year FY2024 number at $353.2 million, down 2.07% from a year prior.
  • Liabilities and Shareholders Equity was $244.7 million for Q3 2025 at Century Therapeutics, down from $284.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $550.3 million in Q1 2022 to a low of $244.7 million in Q3 2025.
  • A 4-year average of $404.3 million and a median of $397.6 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 0.17% in 2024, then plummeted 37.03% in 2025.
  • Century Therapeutics' Liabilities and Shareholders Equity stood at $486.5 million in 2022, then fell by 25.87% to $360.7 million in 2023, then dropped by 2.07% to $353.2 million in 2024, then tumbled by 30.72% to $244.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Liabilities and Shareholders Equity are $244.7 million (Q3 2025), $284.7 million (Q2 2025), and $315.6 million (Q1 2025).